The Diagnostic Imaging MRI modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of MRI across the healthcare continuum, including breast, neurological, cardiovascular, prostate imaging, and more.
September 11th 2025
Abbreviated biparametric MRI demonstrated nearly equivalent detection rates for clinically significant and clinically insignificant prostate cancer as multiparametric MRI, according to research involving 22 centers in 12 countries.
September 11th 2025
Can AI Automate BPE Assessment of Dense Breasts on MRI?
April 3rd 2024An MRI-based machine learning model demonstrated a comparable background parenchymal enhancement (BPE) hazard ratio to that of manual BPE assessment for breast cancer, according to a study of over 4,500 women with dense breasts.
Are Prostate Biopsies Necessary in Patients with Negative or Equivocal MRIs and Low PSA Density?
April 2nd 2024Up to 48 percent of unnecessary prostate biopsies could be eliminated by limiting biopsy to patients with PI-RADS 4 and higher MRI assessments and a prostate-specific antigen density level below 0.15 ng/mL2, according to a new meta-analysis.
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
March 25th 2024The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
Emerging Insights on MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer
March 21st 2024For men with prostate cancer, the use of MRI-guided transurethral ultrasound ablation (TULSA) led to a 92 percent decrease in median prostate volume at one year, according to new research recently presented at Society of Interventional Radiology (SIR) conference.
Study: PET/MRI May Prevent Up to 83 Percent of Unnecessary Biopsies in Men with PI-RADS 3 Lesions
March 15th 2024For men with PI-RADS 3 lesions, PRIMARY scores of 4-5 with PET/MRI had a sensitivity rate of 87.5 percent for clinically significant prostate cancer, according to newly published research.
Study Says Low-Field MRI Offers Sufficient Diagnostic Quality for Detecting Spinal Pathology
March 11th 2024In a study of patients who had lumbar spine MRI exams at 0.55T, 1.5T and 3T, researchers found that 0.55T MRI provided acceptable diagnostic quality across all sequences for varying pathologies including degenerative joint disease, compression fractures and osseous metastatic disease.
Can Autonomous AI Help Reduce Prostate MRI Workloads Without Affecting Quality?
March 1st 2024Based on findings from a multicenter study of over 1,600 patients, researchers at the European Congress of Radiology suggest the inclusion of autonomous artificial intelligence (AI) triage could facilitate up to a 75 percent reduction in prostate MRI reading workload.
ECR Study Examines Key Predictive Factors for Metastasis in Patients with High-Risk Prostate Cancer
February 28th 2024Sixty-five percent of patients with newly diagnosed high-risk prostate cancer may have extraprostatic extension on MRI, and PSMA PET/CT findings suggest those with Gleason scores of eight or higher have more than double the risk of metastasis, according to a new study presented at the European Congress of Radiology (ECR).
Can Non-Contrast Abbreviated MRI be a Viable Alternative for HCC Surveillance?
February 27th 2024A new meta-analysis noted pooled sensitivity and specificity rates of 83 percent and 91 percent, respectively, for the use of non-contrast abbreviated MRI in surveillance of hepatocellular carcinoma (HCC).
MRI Research Suggests Link Between COVID-19 Related Brain Fog and Blood-Brain Barrier Dysfunction
February 23rd 2024For people with COVID-19 related brain fog, emerging dynamic contrast-enhanced MRI (DCE-MRI) research findings revealed blood-brain barrier disruption in multiple brain regions, including temporal lobes and the frontal cortex, up to a year after active infection.